Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RBI-8000
- Development stage
- Unknown
- Lead developer
- Replicate Bioscience
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
**RBI-8000** is a self-replicating RNA (srRNA) therapeutic in early development as a pan-inflammasome inhibitor targeting IL-1 and IL-18 pathways for inflammatory and autoimmune diseases. Developed by Replicate Bioscience, a Duke University spinout leveraging synthetic biology for RNA treatments, it utilizes RNA interference to silence key inflammasome components, enabling prolonged protein suppression at lower doses compared to conventional RNA therapies. The program remains in discovery/preclinical stages with potential broad applications in autoimmunity.[1][6][10][12]
02
Targets
Interleukin-1 beta messenger RNAIL1A (Interleukin 1 alpha)IL18 (Interleukin-18)
Beyond the preview
Go deeper on RBI-8000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RBI-8000.